SOMAVERT is contraindicated in patients with a history of hypersensitivity to any of its components.

Patients on opioids often needed higher serum pegvisomant concentrations to achieve appropriate IGF-I suppression compared with patients not receiving opioids.

Patients with acromegaly and diabetes mellitus being treated with insulin and/or oral hypoglycemic agents may require dose reductions of these therapeutic agents after the initiation of treatment with SOMAVERT.

Important safety information regarding liver test monitoring
Baseline serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), serum total bilirubin (TBIL), and alkaline phosphatase (ALP) levels should be obtained prior to initiating therapy with SOMAVERT. Monitor liver tests based on baseline values and changes during therapy according to the schedule in the full Prescribing Information.

Asymptomatic, transient elevations in transaminases up to 15 times ULN have been observed in <2% of subjects among two open-label trials (with a total of 147 patients). These reports were not associated with an increase in bilirubin. Transaminase elevations normalized with time, most often after suspending treatment. If a patient develops liver test elevations, or any other symptoms of liver dysfunction while receiving SOMAVERT, please see Liver Tests section of the full Prescribing Information.

In subjects with systemic hypersensitivity reactions, caution and close monitoring should be exercised when re-initiating SOMAVERT therapy.

The most common adverse events (>6% and at frequencies greater than placebo) in the active treatment arms in a placebo-controlled study (N=112) included infection (23%), pain (14%), nausea (14%), diarrhea (14%), abnormal liver function tests (12%), flu syndrome (12%), and injection-site reaction (11%).

Lipohypertrophy has been reported in patients treated with SOMAVERT; therefore, injection sites should be rotated daily.

The maximum indicated daily maintenance dose for SOMAVERT is 30 mg.

Rx only


SOMAVERT® (pegvisomant for injection) is indicated for the treatment of acromegaly in patients who have had an inadequate response to surgery or radiation therapy, or for whom these therapies are not appropriate. The goal of treatment is to normalize serum insulin-like growth factor-I (IGF-I) levels.


  1. SOMAVERT [prescribing information]. New York, NY: Pfizer Inc; 2016.
  2. Giustina A, Chanson P, Bronstein MD, et al. A consensus on criteria for cure for acromegaly. J Clin Endocrinol Metab. 2010;95(7):3141-3148.
  3. Trainer PJ, Drake WM, Katznelson L, et al. Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. N Engl J Med. 2000;342(16):1171-1177.
  4. Melmed S. Medical progress: Acromegaly. N Engl J Med. 2006;355(24):2558-2573.
  5. Melmed S, Jackson I, Kleinberg D, Klibanski A. Current treatment guidelines for acromegaly. J Clin Endocrinol Metab. 1998;83(8):2646-2652.
  6. Data on file. Pfizer Inc, New York, NY.
  7. Barkan AL, Burman P, Clemmons DR, et al. Glucose homeostasis and safety in patients with acromegaly converted from long-acting octreotide to pegvisomant. J Clin Endocrinol Metab. 2005;90(10):5684-5691.
  8. van der Lely AJ, Hutson RK, Trainer PJ, et al. Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist. Lancet. 2001;358(9295):1754-1759.
  9. Parkinson C, Drake WM, Roberts ME, Meeran K, Besser GM, Trainer PJ. A comparison of the effects of pegvisomant and octreotide on glucose, insulin, gastrin, cholecystokinin, and pancreatic polypeptide responses to oral glucose and a standard mixed meal. J Clin Endocrinol Metab. 2002;87(4):1797-1804.
  10. Klibanski A, Melmed S, Clemmons DR, et al. The endocrine tumor summit 2008: appraising therapeutic approaches for acromegaly and carcinoid syndrome. Pituitary. 2010;13:266-286.

Treatment Support and Financial Assistance

With SOMAVERT®, patients
receive comprehensive support

Pfizer offers comprehensive services for your patients, including financial assistance for eligible patients, if needed. You can enroll your patients by calling the Pfizer Bridge Program®* at 1-800-645-1280, or fax a completed Statement of Medical Necessity (SMN) to 1-800-479-2562.

The Pfizer Bridge Program® provides assistance with insurance, reimbursement, and financial issues, including copay and coinsurance support.

Dedicated PCC Support

The Pfizer Bridge Program® assigns a dedicated Patient Care Consultant (PCC) to assist with insurance coverage. Your patients’ dedicated PCC provides reimbursement support throughout therapy

  • The same PCC works with your patients and you from SMN initiation through authorization

  • Each PCC is knowledgeable about regional payers and individual plans

  • Your patient's PCC helps research coverage for SOMAVERT® when your patient's insurance changes

Quick Approval Turnaround

  • 7 days average time to approval†

Patient Assistance Program

  • Eligible patients may also qualify for help getting SOMAVERT. For qualified patients, the Patient Assistance Program can provide medicines and supplies at no cost.

SOMAVERT Starter Kit

To help new patients begin SOMAVERT therapy, Pfizer supplies a kit containing several helpful tools. These include a SOMAVERT Injection Placemat, Patient Brochure, injection training DVD, and an initial supply of syringes for injecting SOMAVERT (when a prescription is provided).

Comprehensive self-injection training
Patients can get one-time one-on-one in-home training by qualified nurses. To request training for your patient during enrollment, simply check the “Patient Injection Training Requested” box on the SOMAVERT Statement of Medical Necessity.

*Certain programs and services powered by Pfizer RxPathwaysTM.

Includes new patients as of July 2015.

Copay Information

The SOMAVERT Copay/Coinsurance Support Program can help provide financial assistance for eligible patients.*

Nearly 94% of patients with commercial insurance plans have access to SOMAVERT.6

$5 copay per month for eligibile patients and the rest of their copay/coinsurance is covered with the SOMAVERT Copay/Coinsurance Support Program.

  • The SOMAVERT Copay/Coinsurance Support Program offers up to $20,000/year in assistance for eligible insured patients

  • Rebate options exist for patients whose specialty pharmacies do not recognize the SOMAVERT Copay Program Card

Enrollment in the SOMAVERT Copay Program is easy – ask your Pfizer Representative for more information on enrollment, or you or your patient can contact The Pfizer Bridge Program®‡ by phone (1-800-645-1280) or fax (1-800-479-2562).

Rebate options exist for patients whose specialty pharmacies do not accept the SOMAVERT copay card.

SOMAVERT is available at the following specialty pharmacies

*The SOMAVERT Copay/Coinsurance Support Program is not health insurance. This copay/coinsurance is available only at participating pharmacies. Pfizer reserves the right to rescind, revoke, or amend this offer without notice. No membership fees. Some restrictions may apply. See below for details.

Includes copay and coinsurance, excludes deductible.

tCertain programs and services powered by Pfizer RxPathwaysTM.

Terms and Conditions

By using the SOMAVERT Copay/Coinsurance Support Program Card (the "Card"), patients acknowledge that they currently meet the eligibility criteria and will comply with the terms and conditions described below:

The Card is not valid for prescriptions that are eligible to be reimbursed, in whole or in part, by Medicaid, Medicare, or other federal or state healthcare programs. The Card is not valid for prescriptions that are eligible to be reimbursed by private insurance plans or other health or pharmacy benefit programs that reimburse patients for the entire cost of their prescription drugs. The Card covers copay/coinsurance costs up to $20,000 for a period of 12 months; actual level of assistance will be determined by the Pfizer Bridge Program®. Patients are responsible for a $5 monthly copayment based upon program utilization. Patients must deduct the value received under this program from any reimbursement request submitted to the patient's insurance plan, either directly by the patient or on the patient's behalf. The Card is not valid in Puerto Rico. This program cannot be combined with any other rebate/coupon, free trial, or similar offer for the specified prescription.The Card will be accepted only at participating pharmacies. The Card is not health insurance. No membership fees. Offer good only in the U.S. The Card is limited to 1 per person during this offering period and is not transferable. Pfizer reserves the right to rescind, revoke, or amend this offer without notice. Card and Program expires on the patient eligibility end date. For more information, please call 1-800-645-1280 or visit Pfizer Inc, 235 East 42nd Street, New York, NY 10017.